Continued funding of the IBDWG is dependant upon CME/CE metrics reporting to supporters. If you find the IBDWG an interesting and useful site we would urge you to please remember to complete your applications for CME/CE credits after viewing accredited activities on the IBDWG. There is no fee for this. Should you not require the credits please could you complete the evaluation form at the end of the activity so we can evaluate the program more effectively. Many thanks in advance for you co-operation.
Audio presentations and a core slide library with comprehensive notes, plus ready-to-go presentations.
Ready-to-go Meeting Presentations
Unique diagnostic and therapeutic issues in pediatric inflammatory bowel disease (IBD)
Joel R. Rosh, MD, FAAP, FACG, AGAF
- Therapeutic algorithms for Crohn’s disease: Where are we in 2012?
Brian G. Feagan, MD
- Potential novel therapies - what's in the pipeline (AMA)
Jean-Frédéric Colombel, MD - Audio
Presentation: Discuss the role of the specialist gastroenterology nurse in answering frequently
posed questions raised by IBD patients
Laurie Powers, RN
Archive
(CME-expired materials)
Interactive case scenarios providing best practice solutions to common clinical issues.
Prognostic markers in Crohn's disease: Effects on natural history and clinical outcomes
Maria T. Abreu, MD- Pediatric inflammatory bowel disease: Making a timely diagnosis and instituting effective therapy
Joel R. Rosh, MD, FAAP, FACG, AGAF - Approaches to the
long-term management of ulcerative colitis: Optimizing therapeutic choices and patient outcomes
Bret Lashner, MD
View
all CME active Curbside Consults and Clinical Decision Maps
Expert commentary based on the latest published data with downloadable PowerPoint slides illustrating the key information.
- Treating IBD early: Implications for mucosal healing and disease progression
William Sandborn, MD - IBS and IBD: Similar beginnings, but different endings?
Brian E. Lacy, PhD, MD - Recent advances in the management of mildly-to-moderately active ulcerative colitis
Bret A. Lashner, MD - The
use of prognostic markers to determine disease course and to improve management
Mark Silverberg, MD - Vaccinations and immunizations for patients with inflammatory bowel disease: Who, what, and when?
Gil Y. Melmed, MD, MS
Please provide us with your comments and feedback about this site.
Expert critiques of the most important recent publications in IBD.
Summarized by Gary R. Lichtenstein, MD
This section is eligible for 0.75 AMA PRA Category 1 Credit(s). Please read all articles in the section before applying for CME credits.
- Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis
Sandborn WJ, Ghosh S, Panes J, et al. N Engl J Med 2012; 367: 616–24.
- Ustekinumab induction and maintenance therapy in refractory Crohn’s disease
Sandborn WJ, Gasink C, Gao LL, et al. N Engl J Med 2012; 367: 1519–28.
- Linking long-term dietary patterns with gut microbial enterotypes
Wu GD, Chen J, Hoffman C, et al. Science 2011; 334: 105–8.
- Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
Jostins L, Ripke S, Weersma RK, et al. Nature 2012; 491: 119–24. - Serious infection and mortality in patients with Crohn’s disease: More than 5 years of follow-up in the TREAT™ Registry
Lichtenstien GL, Feagan BG, Cohnen RD, et al. Am J Gastroenterol 2012; 107: 1409–22. - Risk of melanoma and non-melanoma skin cancer among patients with inflammatory bowel disease
Long MD, Martin CF, Pipkin CA, et al. Gastroenterology 2012; 143: 390–9.
